0.54
-0.93%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Broncus Holding
Its shares trade on HKEX under the ticker 2216.HK. It has been listed since 24 September 2021. In the fiscal year to 31 December 2025, it reported revenue of $174,000 and a net loss of $17.9m. At that date it held total assets of $156.1m and shareholders' equity of $149.9m.
Broncus Holding Corp. engages in the research and development, and manufacturing and commercialization of medical device and consumables. The company is headquartered in Hangzhou, Zhejiang. The company went IPO on 2021-09-24. The firm's business includes providing diagnostic solutions, lung cancer treatment solutions, chronic obstructive pulmonary disease solutions and navigation platforms. The diagnostic solutions pruducts include FleXNeedle, ATV Sheath, ATV Balloon and others. The lung cancer treatment solutions products include InterVapor for lung cancer, H-Marker and others. The chronic obstructive pulmonary disease (COPD) solutions products include InterVapor for COPD and TLD Ablation System. The navigation platform products include Lungpoint, Lungpro, New Generation Navigation Platform and others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 24 Sept 2021
- Employees
- 314
- Website
- broncus.com ↗
Leadership
Pay as last reported
- Mr. Hong XuExecutive Chairman of the Board, Chief Executive Officer, Chief Technology Office, since 2021$210,000
- Mr. Todd CornellPresident of Broncus Medical and Uptake Medical
- Mr. Zhenhua LiHead of Sales and Marketing and Clinical Education Affairs in Asia Region
- Ms. Ka Yan SuenCompany Secretary
- Ms. Yanhong KuangNon-Executive Director
- Mr. Ao ZhangNon-Executive Director
- Dr. Pok Man KamNon-Executive Independent Director$13,000
- Dr. David LimNon-Executive Independent Director
- Ms. Yee Sin WongNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Headquartered in Hangzhou, Zhejiang with 314 full-time employees.
- Offers a diverse product portfolio including diagnostic, lung cancer treatment, COPD, and navigation platform solutions.
- Has completed an IPO on 2021-09-24, indicating market entry and capitalization.
Weaknesses
- Operates in a highly regulated health care sector requiring continuous compliance.
- Relies on a limited number of products for revenue generation.
- No mention of international market presence or expansion beyond China.
Opportunities
- Potential growth in diagnostic solutions market with products like FleXNeedle and ATV Sheath.
- Expansion of lung cancer treatment solutions with InterVapor for lung cancer.
- Increasing demand for COPD solutions including InterVapor for COPD and TLD Ablation System.
Threats
- Regulatory challenges in the health care industry may impact operations.
- Competition from other medical device manufacturers in China.
- Dependence on specific product lines for revenue could be risky.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.